PART I . Overview We are a late-stage clinical biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry, biochemistry and virology to discover, develop and commercialize novel, orally administered antivirals to treat serious viral diseases. Our current product candidate pipeline includes the regimen of bemnifosbuvir and ruzasvir which we believe has the potential to improve the current standard of care (SOC) for the treatment of patients with...
Q2 FY2026 — expected 2026-08-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001193125-26-094159 | EDGAR | 101K words |
| 2025-03-06 | 2024-12-31 | 0000950170-25-034808 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0000950170-24-022226 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0000950170-23-005186 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001564590-22-007672 | EDGAR | — |
| 2021-03-30 | 2020-12-31 | 0001564590-21-016724 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277815 | EDGAR | 67K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105123 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069367 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123447 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092914 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059699 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061213 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039920 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018869 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022699 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015570 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0000950170-22-008732 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-05 | 0001193125-26-093961 | EDGAR | 4K words |
| 2026-01-08 | 0001193125-26-007081 | EDGAR | — |
| 2025-11-12 | 0001193125-25-277627 | EDGAR | — |
| 2025-08-07 | 0001193125-25-175433 | EDGAR | — |
| 2025-06-20 | 0001193125-25-143750 | EDGAR | — |
| 2025-05-12 | 0001193125-25-117809 | EDGAR | — |
| 2025-04-17 | 0001193125-25-083523 | EDGAR | — |
| 2025-04-01 | 0001193125-25-069932 | EDGAR | — |
| 2025-03-24 | 0001193125-25-060794 | EDGAR | — |
| 2025-03-06 | 0001193125-25-048426 | EDGAR | — |
69 total filings indexed. 41 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001593899 |
| Ticker | AVIR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | MA |
| Website | https://www.ateapharma.com |
| Listed | 2020-10-30 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report